Tags : Paratek Pharmaceuticals

Paratek Pharmaceuticals’ Nuzyra (omadacycline) Receives FDA Approval for Community-Acquired Bacterial

Shots: The approval is based on multiple trial study assessing Nuzyra and resulted in safe, efficacious and well tolerated results Nuzyra (omadacycline) is a qd IV PO tetracycline class antibacterial drug indicated to treat CABP and  ABSSSI Post marketing approval, Paratek’s plans to evaluate Nuzyra for the treatment of CABP and pediatrics, with its expected […]Read More